Laddar...
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. Phase II dose-finding and pharmacodynamic studies identified the 20 µg once-daily dose as having the optimum combination of efficacy, convenience and tolerability. Lixise...
Sparad:
| I publikationen: | Diabetes Ther |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer Healthcare
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4269639/ https://ncbi.nlm.nih.gov/pubmed/25027491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0073-z |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|